VICL (Vical Labs) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VICL (Vical Labs)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: bob zagorin	4/7/2006 12:08:14 PM
	of 1972

GS Vical Inc. EPS (FY Dec) 2006E ($0.92), 2007E ($1.02) Underperform/Neutral (VICL) $5.92 At Vicals Analyst Day, management highlighted the companys novel vaccines for cytomegalovirus (CMV) and influenza. DNA-based vaccines are safer, easier to manufacture and potentially more effective. However, the programs are relatively early in development. A P2 trial in CMV for transplant in blood cancer patients started 2/06 with potential results in 2007. A pandemic flu vaccine may enter P1 studies in 2006. VICL has a broad technology platform in DNA gene delivery, solid partners, and 2 years cash position. We maintain our Underperform rating while awaiting progress on proprietary projects. Our coverage view remains Neutral. Risks to our rating include acceleration of pipeline, avian flu pandemic, and acquisition potential.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next